This week, drug maker AstraZeneca requested an emergency use authorization (EUA) from the Food and Drug Administration for its long-acting antibody combination designed to prevent symptomatic COVID-19. According to AstraZeneca, phase 3 trial data showed AZD7442, when administered pre-exposure as prophylaxis, reduced the risk of developing symptomatic COVID-19 by 77%. (Astra Zeneca news release, 10/5/21)
